Background: Adequate lymphadenectomy is a key determinant of oncologic outcomes in right-sided colon cancer, influencing staging accuracy, adjuvant therapy and long-term survival. D3 lymphadenectomy combined with Complete Mesocolic Excision (CME) has demonstrated superior nodal yield and oncologic clearance compared with conventional resections. However, the laparoscopic approach remains technically demanding and prospective data from the Indian subcontinent are limited. This study aimed to evaluate the feasibility, safety and short-term oncologic outcomes of laparoscopic D3 right hemicolectomy. Methods: This prospective observational study was conducted at a tertiary care teaching hospital between January 2018 and December 2025. Patients aged =18 years with histologically confirmed right-sided colon adenocarcinoma undergoing elective laparoscopic D3 right hemicolectomy were included. A standardized medial-to-lateral approach with central vascular ligation and CME was used in all cases. Primary outcomes included feasibility, lymph node yield and R0 resection rate, while secondary outcomes included operative parameters, postoperative recovery and 30-day morbidity and mortality. Results: A total of 142 patients underwent laparoscopic D3 right hemicolectomy. All procedures were completed laparoscopically with a conversion rate of 0%. The mean operative time was 146±34 minutes and mean intraoperative blood loss ranged from 100 to 150 mL. The mean lymph node yield was 45±8.4. R0 resection was achieved in all patients. Early postoperative recovery was observed, with tolerance of solid oral diet at a mean of 24 hours and a mean hospital stay of 7 days. Major complications included anastomotic leak in 3 patients (2.1%) and wound-related complications in 5%, with no 30-day mortality. Conclusion: Laparoscopic D3 right hemicolectomy is a safe, feasible and oncologically sound procedure in experienced centers. The high lymph node yield, zero conversion rate and acceptable morbidity support its role in the management of right-sided colon cancer. Further multicentric studies with long-term follow-up are required to establish survival benefits.